Sinister Scheduling

Insys Therapeutics made headlines again this week over the DEA's classification of their new marijuana-derivative drug.Insys Therapeutics made headlines again this week not for their slew of lawsuits over pushing deadly opioid drugs and exacerbating the country's opioid crisis, but for the DEA's classification of their new marijuana-derivative drug. The new synthetic THC spray, Syndros (surprisingly not the name of main villain in the recently released Justice League movie), received a Schedule